118 related articles for article (PubMed ID: 38748739)
1. Safety and efficacy of peptide receptor radionuclide therapy in neuroendocrine tumors: A single center experience.
Sukrithan V; Armbruster H; Rogers S; Vogt SM; Grenade C; Verschraegen C; Zhou Y; Goyal A; Natwa M; Hussein A; Barr H; Konate D; Batdorf R; Brown A; Williams B; Zhao S; Wei L; Xu M; Shah MH; Konda B
PLoS One; 2024; 19(5):e0298824. PubMed ID: 38748739
[TBL] [Abstract][Full Text] [Related]
2. 177Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated with Chemotherapy: Analysis of Outcome, Safety, and Their Determinants.
Fröss-Baron K; Garske-Roman U; Welin S; Granberg D; Eriksson B; Khan T; Sandström M; Sundin A
Neuroendocrinology; 2021; 111(4):330-343. PubMed ID: 32097917
[TBL] [Abstract][Full Text] [Related]
3. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
Parghane RV; Talole S; Prabhash K; Basu S
Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500
[TBL] [Abstract][Full Text] [Related]
4. 177Lu-DOTATATE PRRT in Patients with Metastatic Neuroendocrine Tumor and a Single Functioning Kidney: Tolerability and Effect on Renal Function.
Ranade R; Basu S
J Nucl Med Technol; 2016 Jun; 44(2):65-9. PubMed ID: 26848166
[TBL] [Abstract][Full Text] [Related]
5. Renal and hematological toxicity in patients of neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-DOTATATE.
Gupta SK; Singla S; Bal C
Cancer Biother Radiopharm; 2012 Nov; 27(9):593-9. PubMed ID: 23009580
[TBL] [Abstract][Full Text] [Related]
6. Laboratory, Clinical, and Survival Outcomes Associated With Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors.
Kipnis ST; Hung M; Kumar S; Heckert JM; Lee H; Bennett B; Soulen MC; Pryma DA; Mankoff DA; Metz DC; Eads JR; Katona BW
JAMA Netw Open; 2021 Mar; 4(3):e212274. PubMed ID: 33755166
[TBL] [Abstract][Full Text] [Related]
7. Resistant functioning and/or progressive symptomatic metastatic gastroenteropancreatic neuroendocrine tumors: efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy in this setting.
Kalshetty A; Ramaswamy A; Ostwal V; Basu S
Nucl Med Commun; 2018 Dec; 39(12):1143-1149. PubMed ID: 30308585
[TBL] [Abstract][Full Text] [Related]
8. Improving quality of life in patients with pancreatic neuroendocrine tumor following peptide receptor radionuclide therapy assessed by EORTC QLQ-C30.
Marinova M; Mücke M; Mahlberg L; Essler M; Cuhls H; Radbruch L; Conrad R; Ahmadzadehfar H
Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):38-46. PubMed ID: 28864881
[TBL] [Abstract][Full Text] [Related]
9. Survival predictors of
Swiha MM; Sutherland DEK; Sistani G; Khatami A; Abazid RM; Mujoomdar A; Wiseman DP; Romsa JG; Reid RH; Laidley DT
J Cancer Res Clin Oncol; 2022 Jan; 148(1):225-236. PubMed ID: 34110489
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Efficacy, Survival, and Safety of [
Brabander T; van der Zwan WA; Teunissen JJM; Kam BLR; Feelders RA; de Herder WW; van Eijck CHJ; Franssen GJH; Krenning EP; Kwekkeboom DJ
Clin Cancer Res; 2017 Aug; 23(16):4617-4624. PubMed ID: 28428192
[No Abstract] [Full Text] [Related]
11. Feasibility and utility of re-treatment with (177)Lu-DOTATATE in GEP-NENs relapsed after treatment with (90)Y-DOTATOC.
Severi S; Sansovini M; Ianniello A; Bodei L; Nicolini S; Ibrahim T; Di Iorio V; D'Errico V; Caroli P; Monti M; Paganelli G
Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1955-63. PubMed ID: 26112388
[TBL] [Abstract][Full Text] [Related]
12. Safety and Effectiveness of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy After Regional Hepatic Embolization in Patients With Somatostatin-Expressing Neuroendocrine Tumors.
Hamiditabar M; Ali M; Bolek L; Vahdati G; Tworowska I; Delpassand ES
Clin Nucl Med; 2017 Nov; 42(11):822-828. PubMed ID: 28832377
[TBL] [Abstract][Full Text] [Related]
13. Rapid Progression After 177Lu-DOTATATE in Patients With Neuroendocrine Tumors.
Assi HA; Hornbacker K; Shaheen S; Wittenberg T; Silberman R; Kunz PL
Pancreas; 2021 Jul; 50(6):890-894. PubMed ID: 34398071
[TBL] [Abstract][Full Text] [Related]
14. Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience.
Delpassand ES; Samarghandi A; Zamanian S; Wolin EM; Hamiditabar M; Espenan GD; Erion JL; O'Dorisio TM; Kvols LK; Simon J; Wolfangel R; Camp A; Krenning EP; Mojtahedi A
Pancreas; 2014 May; 43(4):518-25. PubMed ID: 24632546
[TBL] [Abstract][Full Text] [Related]
15. Long-term results and tolerability of tandem peptide receptor radionuclide therapy with
Kunikowska J; Pawlak D; Bąk MI; Kos-Kudła B; Mikołajczak R; Królicki L
Ann Nucl Med; 2017 Jun; 31(5):347-356. PubMed ID: 28316066
[TBL] [Abstract][Full Text] [Related]
16. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
17. Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors.
Nicolini S; Bodei L; Bongiovanni A; Sansovini M; Grassi I; Ibrahim T; Monti M; Caroli P; Sarnelli A; Diano D; Di Iorio V; Grana CM; Cittanti C; Pieri F; Severi S; Paganelli G
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3260-3267. PubMed ID: 33604690
[TBL] [Abstract][Full Text] [Related]
18. High clinical and morphologic response using
Kong G; Callahan J; Hofman MS; Pattison DA; Akhurst T; Michael M; Eu P; Hicks RJ
Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):476-489. PubMed ID: 27678267
[TBL] [Abstract][Full Text] [Related]
19. Peptide receptor radionuclide therapy with (90)Y-DOTATATE/(90)Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicity.
Vinjamuri S; Gilbert TM; Banks M; McKane G; Maltby P; Poston G; Weissman H; Palmer DH; Vora J; Pritchard DM; Cuthbertson DJ
Br J Cancer; 2013 Apr; 108(7):1440-8. PubMed ID: 23492685
[TBL] [Abstract][Full Text] [Related]
20. 177Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update.
Demirci E; Kabasakal L; Toklu T; Ocak M; Şahin OE; Alan-Selcuk N; Araman A
Nucl Med Commun; 2018 Aug; 39(8):789-796. PubMed ID: 29912750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
